These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 31538821)

  • 1. The role of obinutuzumab in the management of follicular lymphoma.
    O'Nions J; Townsend W
    Future Oncol; 2019 Nov; 15(31):3565-3578. PubMed ID: 31538821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. An Evidence-based Review of Anti-CD20 Antibody-containing Regimens for the Treatment of Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia, Diffuse Large B-cell Lymphoma, or Follicular Lymphoma.
    Falchi L; Ferrajoli A; Jacobs I; Nava-Parada P
    Clin Lymphoma Myeloma Leuk; 2018 Aug; 18(8):508-518.e14. PubMed ID: 29934061
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improving CD20 antibody therapy: obinutuzumab in lymphoproliferative disorders.
    Prica A; Crump M
    Leuk Lymphoma; 2019 Mar; 60(3):573-582. PubMed ID: 30668192
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics, exposure, efficacy and safety of obinutuzumab in rituximab-refractory follicular lymphoma patients in the GADOLIN phase III study.
    Gibiansky E; Gibiansky L; Buchheit V; Frey N; Brewster M; Fingerle-Rowson G; Jamois C
    Br J Clin Pharmacol; 2019 Sep; 85(9):1935-1945. PubMed ID: 31050355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Obinutuzumab in follicular lymphoma.
    Martinez-Calle N; Figueroa-Mora R; Villar-Fernandez S; Marcos-Jubilar M; Panizo C
    Drugs Today (Barc); 2016 Dec; 52(12):643-651. PubMed ID: 28276536
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody Therapy Maintenance in Follicular Lymphoma.
    Golfier C; Salles G
    Hematol Oncol Clin North Am; 2020 Aug; 34(4):689-699. PubMed ID: 32586574
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label phase 1b study of obinutuzumab plus lenalidomide in relapsed/refractory follicular B-cell lymphoma.
    Morschhauser F; Salles G; Le Gouill S; Tilly H; Thieblemont C; Bouabdallah K; Fabiani B; Ménard C; Tarte K; Cartron G; Houot R
    Blood; 2018 Oct; 132(14):1486-1494. PubMed ID: 30068505
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Obinutuzumab for the First-Line Treatment of Follicular Lymphoma.
    Marcus R; Davies A; Ando K; Klapper W; Opat S; Owen C; Phillips E; Sangha R; Schlag R; Seymour JF; Townsend W; Trněný M; Wenger M; Fingerle-Rowson G; Rufibach K; Moore T; Herold M; Hiddemann W
    N Engl J Med; 2017 Oct; 377(14):1331-1344. PubMed ID: 28976863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Combination therapy with the type II anti-CD20 antibody obinutuzumab.
    Klein C; Bacac M; Umana P; Fingerle-Rowson G
    Expert Opin Investig Drugs; 2017 Oct; 26(10):1145-1162. PubMed ID: 28845710
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of patients with follicular lymphoma treated first line with obinutuzumab.
    Opat S; Dickinson M; Cheah CY; Tam C; Boulos J; Thorburn AN; Trotman J
    Asia Pac J Clin Oncol; 2019 May; 15 Suppl 3():3-11. PubMed ID: 31058467
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Fatal disseminated enterovirus infection in a patient with follicular lymphoma undergoing obinutuzumab maintenance therapy.
    Heger JM; Eichenauer DA; Kasper P; Böll B; Shimabukuro-Vornhagen A; Kochanek M
    Eur J Haematol; 2019 Sep; 103(3):268-271. PubMed ID: 31211882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Phase 2 multicentre study of single-agent ofatumumab in previously untreated follicular lymphoma: CALGB 50901 (Alliance).
    Rosenbaum CA; Jung SH; Pitcher B; Bartlett NL; Smith SM; Hsi E; Wagner-Johnston N; Thomas SP; Leonard JP; Cheson BD
    Br J Haematol; 2019 Apr; 185(1):53-64. PubMed ID: 30723894
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The societal impact of obinutuzumab in the first-line treatment of patients with follicular lymphoma in Germany.
    Hofmann S; Himmler S; Ostwald D; Dünzinger U; Launonen A; Thuresson PO
    J Comp Eff Res; 2020 Oct; 9(14):1017-1026. PubMed ID: 33016109
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One Size Does Not Fit All: Who Benefits From Maintenance After Frontline Therapy for Follicular Lymphoma?
    Roschewski M; Hill BT
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():467-476. PubMed ID: 31099693
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A retrospective study on the management of patients with rituximab refractory follicular lymphoma.
    Solal-Céligny P; Leconte P; Bardet A; Hernandez J; Troussard X
    Br J Haematol; 2018 Jan; 180(2):217-223. PubMed ID: 29230799
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety.
    Hiddemann W; Barbui AM; Canales MA; Cannell PK; Collins GP; Dürig J; Forstpointner R; Herold M; Hertzberg M; Klanova M; Radford J; Seymour JF; Tobinai K; Trotman J; Burciu A; Fingerle-Rowson G; Wolbers M; Nielsen T; Marcus RE
    J Clin Oncol; 2018 Aug; 36(23):2395-2404. PubMed ID: 29856692
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Obinutuzumab in the treatment of B-cell malignancies: a comprehensive review.
    Davies A; Kater AP; Sharman JP; Stilgenbauer S; Vitolo U; Klein C; Parreira J; Salles G
    Future Oncol; 2022 Aug; 18(26):2943-2966. PubMed ID: 35856239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line obinutuzumab for follicular lymphoma.
    Baker H
    Lancet Oncol; 2017 Nov; 18(11):e648. PubMed ID: 29033196
    [No Abstract]   [Full Text] [Related]  

  • 20. Is there a role for a maintenance rituximab in indolent lymphoproliferative diseases other than follicular lymphoma?
    Moccia AA; Zucca E; Ghielmini M
    Leuk Lymphoma; 2017 Jan; 58(1):30-36. PubMed ID: 27813427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.